Local News

• Court in Denmark upholds two Lipitor patents, prevents launch of Ranbaxy generic product  Pfizer said that the Eastern Division of the High Court in Copenhagen, Denmark has ruled in the company's favor in challenges to two of its patents covering atorvastatin, the active ingredient in Lipitor. The basic and enantiomer patents were challenged by generics manufacturer Ranbaxy.
  Pfizer Inc. August 29, 2008  
• Aastrom Biosciences reports fourth quarter and fiscal year 2008 financial results  Aastrom Biosciences reported financial results for the fourth quarter and fiscal year ended June 30, 2008. Total revenues for the quarter and twelve months ended June 30, 2008 were $149,000 and $522,000, respectively, compared to $165,000 and $685,000 for the same periods in fiscal year 2007.
  Aastrom Biosciences, Inc. August 29, 2008  
• GSK signs $820M drug development deal  GlaxoSmithKline has signed a drug development deal worth as much as $820 million with California company Valeant Pharmaceuticals. Under terms of the deal, Valeant gives GlaxoSmithKline the worldwide development and commercialization rights to the drug retigabine.
  Triangle Business Journal August 28, 2008  
• The CYPHER(R) Stent outperforms the Taxus(R) Stent in people with diabetes  In patients with diabetes, the CYPHER(R) Sirolimus-eluting Coronary Stent outperformed the Taxus(R) Stent with lower rates of in-segment restenosis, target lesion revascularization and major adverse events at nine months according to clinical data.
  Johnson & Johnson August 28, 2008  
• Monsanto and Evogene collaborate on yield and stress research  Monsanto Company and Evogene have entered into a five-year research and development collaboration focused on identifying key plant genes related to yield, environmental stress and fertilizer utilization.
  Monsanto Company August 28, 2008  
• Amgen alters anemia drug discounts  Amgen is halting some pricing practices that critics say were contributing to overuse of its flagship anemia drug Aranesp at a time of mounting concerns about the product's safety.
  The New York Times August 27, 2008  Andrew Pollack
• CYPHER SELECT(R) Plus Sirolimus-eluting Coronary Stent receives CE Mark approval  Cordis Corporation announced that it has received CE mark approval to market the CYPHER SELECT(R) Plus Sirolimus-eluting Coronary Stent for the treatment of acute myocardial infarction (AMI), more commonly known as a heart attack.
  Johnson & Johnson August 27, 2008  
• Amylin Pharmaceuticals and Eli Lilly provide context for FDA alert for BYETTA  Amylin Pharmaceuticals and Eli Lilly and Company in a conference call provided context and additional information regarding the August 18, 2008 U.S. Food and Drug Administration (FDA) update to a prior alert for BYETTA(R) (exenatide) injection referencing pancreatitis.
  Amylin Pharmaceuticals, Inc. August 26, 2008  
• Bristol-Myers Squibb and Pfizer provide update on apixaban clinical development program  Bristol-Myers Squibb Company and Pfizer provided an update on the apixaban clinical development program. The companies announced that new Phase II data in acute coronary syndrome patients (ACS) will be presented at the upcoming meeting of the European Society of Cardiology (ESC).
  Pfizer Inc. August 26, 2008  
• VYVANSE(R) now available in U.S. pharmacies nationwide in six dosage strengths  Shire Limited has announced that VYVANSE is now available in U.S. pharmacies nationwide in three additional dosage strengths, bringing the total number to six: 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, and 70 mg.
  Shire August 26, 2008  

   (next 10 articles)